LivaNova PLC Ordinary Shares

LivaNova trades at a remarkable 3.4x sales multiple—extraordinarily cheap for a medical device company with proprietary neuromodulation technology. The stock's RSI of 41.8 sits squarely in neutral territory, suggesting neither oversold desperation nor overbought froth, while the absence of disclosed short interest data leaves squeeze potential unknowable. Trading well below its 52-week high with an unprofitable trailing P/E indicates the market remains skeptical about earnings trajectory despite the company's commanding market position in vagus nerve stimulation. The valuation screams either a genuine deep-value opportunity in a clinical-stage pivoting company or a cautionary signal that consensus growth assumptions are unrealistic.